Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 3008 (118th)

Drug Shortage Prevention Act of 2023

referredUnited States· United States Congress· EN

Introduced

28 April 2023

Last action

5 May 2023 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. Jacobs, Sara [D-CA-51], Colin Allred, Rep. Clarke, Yvette D. [D-NY-9], Rep. Doggett, Lloyd [D-TX-37], Rep. García, Jesús G. "Chuy" [D-IL-4], Rep. Grijalva, Raúl M. [D-AZ-7], Rep. Huffman, Jared [D-CA-2], Rep. Khanna, Ro [D-CA-17], Rep. Larson, John B. [D-CT-1], Rep. Lee, Barbara [D-CA-12], Rep. McGovern, James P. [D-MA-2], Rep. Ocasio-Cortez, Alexandria [D-NY-14], Rep. Pressley, Ayanna [D-MA-7], Rep. Veasey, Marc A. [D-TX-33], Rep. Velázquez, Nydia M. [D-NY-7], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Carter, Troy A. [D-LA-2], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Cohen, Steve [D-TN-9], Rep. Cleaver, Emanuel [D-MO-5], Rep. Smith, Adam [D-WA-9], Sen. Blunt Rochester, Lisa [D-DE], Rep. Crockett, Jasmine [D-TX-30], Rep. Kuster, Ann M. [D-NH-2], Rep. Tokuda, Jill N. [D-HI-2], Yadira Caraveo, Sen. Schiff, Adam B. [D-CA], Rep. Jackson Lee, Sheila [D-TX-18], Sen. Kim, Andy [D-NJ], Rep. Mills, Cory [R-FL-7], Rep. Castor, Kathy [D-FL-14], Rep. Craig, Angie [D-MN-2], Sen. Slotkin, Elissa [D-MI], Rep. Bice, Stephanie I. [R-OK-5], Rep. Sarbanes, John P. [D-MD-3], Rep. Dean, Madeleine [D-PA-4], Rep. Ryan, Patrick [D-NY-18], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Davids, Sharice [D-KS-3], Rep. Fletcher, Lizzie [D-TX-7], Rep. Cárdenas, Tony [D-CA-29], Rep. Peters, Scott H. [D-CA-50], Rep. Hoyle, Val T. [D-OR-4], Rep. Frost, Maxwell [D-FL-10], Rep. Leger Fernandez, Teresa [D-NM-3], Rep. Lynch, Stephen F. [D-MA-8], Rep. Quigley, Mike [D-IL-5], Rep. Pappas, Chris [D-NH-1]

Subjects

Healthcare

Source updated

27 May 2025

Healthcare

Summary

Drug Shortage Prevention Act of 2023 This bill requires drug manufacturers to notify the Food and Drug Administration (FDA) if there is an increased demand for certain critical essential medicines that may result in a shortage. Currently, drug manufacturers are required to notify the FDA in the event of a discontinuation or interruption in the supply of prescription drugs that are life-supporting, life-sustaining, or used for a debilitating disease or condition, including those used in medical emergencies, surgeries, or public health emergencies. The bill requires drug manufacturers to also notify the FDA if there is an increased demand for such drugs that lasts for at least six weeks and that may result in a shortage. Manufacturers must initially notify the FDA of the increased demand within 48 hours after this six-week period and must submit an additional notice within 30 days of the initial notification. The notice must include the reasons for the increased demand, the expected duration, and any other information the FDA requires. The bill's requirements apply to both prescription and nonprescription drugs.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 28 April 2023

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 28 April 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 28 April 2023

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 5 May 2023

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 28 April 2023

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 28 April 2023

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 28 April 2023

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Showing 48 of 51 sponsors and actors.

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.